Picture of MGC Pharmaceuticals logo

MXC MGC Pharmaceuticals Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-15.16%
3m-26.83%
6m-38.5%
1yr-68.02%
Volume Change (%)
10d/3m-69.54%
Price vs... (%)
52w High-75%
50d MA-10.52%
200d MA-33.82%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-189.46%
Return on Equity-206.87%
Operating Margin-434.44%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202330th Jun 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of MGC Pharmaceuticals EPS forecast chart

Profile Summary

MGC Pharmaceuticals Ltd is an Australia-based biopharma company. The Company is primarily focused on the development and supply of standardized phytomedicines to patients globally. It has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy, and CogniCann, in a Phase II trial for symptomatic relief of Dementia. Its products also include CannEpil, MP 100, MP 1:30, MP 1:1, MP 15:1 and MP 25T. The Company is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. It has a product offering targeting two medical conditions, which include epilepsy and dementia. The Company’s wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd and Medicinal Cannabis Clinics Pty Ltd.

Directors

Last Annual
June 30th, 2022
Last Interim
June 30th, 2022
Incorporated
October 21st, 2005
Public Since
December 21st, 2006
No. of Shareholders
10,522
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
2,728,293,852

MXC Share Price Performance

Upcoming Events for MXC

Half Year 2023 MGC Pharmaceuticals Ltd Earnings Release

Similar to MXC

Picture of Acrux logo

Acrux

au flag iconAustralian Stock Exchange - SEATS

Picture of AFT Pharmaceuticals logo

AFT Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

Picture of Auscann group logo

Auscann group

au flag iconAustralian Stock Exchange - SEATS

Picture of Biome Australia logo

Biome Australia

au flag iconAustralian Stock Exchange - SEATS

Picture of Botanix Pharmaceuticals logo

Botanix Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

FAQ

Or unlock with your email

Or unlock with your email